Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol-Myers Squibb Company Receives European Commission Approval of Zeposia for Use in Adults with Moderately to Severely Active Ulcerative Colitis

11/23/2021 | 06:59am EST

Bristol-Myers Squibb Company announced the European Commission has granted a Marketing Authorization for Zeposia (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. Zeposia, an oral medication taken once daily,is a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). Zeposia is the first and only oral S1P receptor modulator approved for UC, and represents a new way of treating this chronic immune-mediated disease. The approval was based on data from True North, a pivotal Phase 3 trial evaluating Zeposia as an induction and maintenance therapy versus placebo in adult patients with moderately to severely active UC. Key findings from the trial include: During induction at Week 10 (Zeposia N=429 versus placebo N=216) the trial met its primary endpoint of clinical remissiona (18% versus 6%, p


ę S&P Capital IQ 2021
All news about BRISTOL-MYERS SQUIBB COMPANY
01/11Evotec, Bristol Myers Expand Neurogenerative Partnership to Include New Targeted Protei..
MT
01/11Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination ..
AQ
01/11Evogene's Biomica Gets Israeli Nod To Move Ahead With Cancer Trial
MT
01/10BioAlta, Bristol Myers Squibb Partnering on Potential Cancer Treatments
MT
01/10BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab ..
PR
01/10Bioatla, Inc. Enters into a Clinical Collaboration with Bristol Myers Squibb to Investi..
CI
01/10Century Therapeutics, Bristol Myers Squibb Sign Cancer Research Collaboration Agreement
MT
01/10Century Therapeutics Shares Rise 12% Premarket After Bristol Myers Deal
DJ
01/10BRISTOL MYERS SQUIBB : JP Morgan Presentation
PU
01/10BRISTOL MYERS SQUIBB CO : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Financials (USD)
Sales 2021 46 405 M - -
Net income 2021 6 271 M - -
Net Debt 2021 28 505 M - -
P/E ratio 2021 21,9x
Yield 2021 3,03%
Capitalization 144 B 144 B -
EV / Sales 2021 3,72x
EV / Sales 2022 3,41x
Nbr of Employees 30 250
Free-Float -
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 64,89 $
Average target price 71,79 $
Spread / Average Target 10,6%
EPS Revisions
Managers and Directors
Giovanni Caforio Senior Vice President-US Oncology
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY4.07%144 033
JOHNSON & JOHNSON-2.32%439 907
ROCHE HOLDING AG-3.75%322 066
PFIZER, INC.-8.37%303 712
ABBVIE INC.1.02%241 811
ELI LILLY AND COMPANY-10.55%223 992